• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AC Immune SA - Common Stock (NQ:ACIU)

    2.120 -0.140 (-6.19%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 560,617
    Open 2.220
    Bid (Size) 2.090 (100)
    Ask (Size) 2.340 (3,800)
    Prev. Close 2.260
    Today's Range 2.095 - 2.220
    52wk Range 1.650 - 4.000
    Shares Outstanding 99,197,829
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
    From AC Immune SA
    Via GlobeNewswire

    Performance

    YTD
    -36.9%
    -36.9%
    1 Month
    -25.1%
    -25.1%
    3 Month
    -30.3%
    -30.3%
    6 Month
    -16.5%
    -16.5%
    1 Year
    +1.0%
    +1.0%

    More News

    Read More
    News headline image
    AC Immune First Quarter 2026 Financial and Corporate Updates
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    Why AC Immune Stock Zoomed Almost 15% Higher Today ↗
    Via The Motley Fool
    News headline image
    AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    Unusual volume stocks in Friday's session ↗
    Via Chartmill
    News headline image
    Why Is AC Immune Stock Up Over 23% Today? ↗
    Via Stocktwits
    News headline image
    AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune to Present at the Jefferies 2025 London Healthcare Conference
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    From AC Immune SA
    Via GlobeNewswire
    News headline image
    AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
    From AC Immune SA
    Via GlobeNewswire

    Frequently Asked Questions

    Is AC Immune SA - Common Stock publicly traded?
    Yes, AC Immune SA - Common Stock is publicly traded.
    What exchange does AC Immune SA - Common Stock trade on?
    AC Immune SA - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for AC Immune SA - Common Stock?
    The ticker symbol for AC Immune SA - Common Stock is ACIU on the Nasdaq Stock Market
    What is the current price of AC Immune SA - Common Stock?
    The current price of AC Immune SA - Common Stock is 2.120
    When was AC Immune SA - Common Stock last traded?
    The last trade of AC Immune SA - Common Stock was at 06/10/26 04:00 PM ET
    What is the market capitalization of AC Immune SA - Common Stock?
    The market capitalization of AC Immune SA - Common Stock is 210.30M
    How many shares of AC Immune SA - Common Stock are outstanding?
    AC Immune SA - Common Stock has 210M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.